Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. SLS-005 for the potential treatment of Sanfilippo Syndrome requires additional natural history data, which is being considered. Co. is also developing several preclinical programs, including SLS-004 and SLS-007, for the potential treatment of Parkinson's Disease. The SEEL stock yearly return is shown above.
The yearly return on the SEEL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SEEL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|